Last Updated : July 24, 2024
Details
Generic Name:
sofosbuvir / velpatasvir
Project Status:
Not filed
Therapeutic Area:
Hepatitis C, chronic
Manufacturer:
Gilead Sciences Canada, Inc.
Brand Name:
Epclusa
Project Line:
Reimbursement Review
Project Number:
NS0024-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients ? 12 years of age pediatric patients ? 12 years of age and weighing ? 30 kg without cirrhosis or with compensated cirrhosis.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024